Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 22, 2026, regarding an event that occurred on April 17, 2026. Vivos Therapeutics, Inc., a Delaware corporation, reported receiving a notice from The Nasdaq Stock Market LLC (Nasdaq) concerning its compliance with continued listing standards.
Key Financial Metrics
- Stockholders' Equity: As of December 31, 2025, the Company reported negative stockholders' equity of approximately $1.55 million.
- Minimum Requirement: Nasdaq Listing Rule 5550(b)(1) requires a minimum stockholders' equity of $2,500,000.
- Recent Financing: During the first quarter ended March 31, 2026, the Company raised aggregate gross proceeds of $6.8 million through a $4.6 million warrant exercise inducement and a $2.25 million private placement.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels for the current period.
Material Changes and Listing Status
The Company received a deficiency notice from Nasdaq indicating that its stockholders' equity as reported in its 2025 Form 10-K did not meet the $2.5 million minimum requirement. The notice has no immediate impact on the listing of the Company's common stock. The Company has taken affirmative steps to remedy the deficiency through recent equity financings, though these transactions alone do not cure the requirement.
Outlook, Risks, and Contingencies
- Compliance Timeline: The Company has 45 calendar days (until June 1, 2026) to submit a plan to regain compliance.
- Extension Possibility: If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days (through October 14, 2026) to achieve compliance.
- Delisting Risk: If the plan is not accepted or compliance is not achieved within the extension period, Nasdaq may issue a delisting determination. The Company would be entitled to request a hearing, which would stay the delisting action.
- Management Commentary: Management cautions that there are no assurances that efforts to comply will be successful. Delisting would have a material adverse effect on the Company's operations and reputation.
Key Facts for Investor Verification
- Verify the Company's submission of a compliance plan to Nasdaq by June 1, 2026.
- Monitor the acceptance status of the compliance plan by the Nasdaq Listing Qualifications Staff.
- Track future equity financing activities or operational improvements required to reach the $2.5 million equity threshold.
- Review the Company's 2025 Form 10-K for detailed financial statements regarding the negative equity position.